GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CardioGenics Holdings Inc (OTCPK:CGNH) » Definitions » Debt-to-Equity

CardioGenics Holdings (CardioGenics Holdings) Debt-to-Equity : -0.21 (As of Jan. 2016)


View and export this data going back to 2004. Start your Free Trial

What is CardioGenics Holdings Debt-to-Equity?

CardioGenics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2016 was $0.38 Mil. CardioGenics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2016 was $0.00 Mil. CardioGenics Holdings's Total Stockholders Equity for the quarter that ended in Jan. 2016 was $-1.79 Mil. CardioGenics Holdings's debt to equity for the quarter that ended in Jan. 2016 was -0.21.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CardioGenics Holdings's Debt-to-Equity or its related term are showing as below:

CGNH's Debt-to-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.23
* Ranked among companies with meaningful Debt-to-Equity only.

CardioGenics Holdings Debt-to-Equity Historical Data

The historical data trend for CardioGenics Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardioGenics Holdings Debt-to-Equity Chart

CardioGenics Holdings Annual Data
Trend Jul06 Jul07 Jul08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 -0.02 -0.56 -0.06 -0.05

CardioGenics Holdings Quarterly Data
Apr11 Jul11 Oct11 Jan12 Apr12 Jul12 Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Jul15 Oct15 Jan16
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.08 -0.08 -0.05 -0.21

Competitive Comparison of CardioGenics Holdings's Debt-to-Equity

For the Diagnostics & Research subindustry, CardioGenics Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CardioGenics Holdings's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CardioGenics Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CardioGenics Holdings's Debt-to-Equity falls into.



CardioGenics Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CardioGenics Holdings's Debt to Equity Ratio for the fiscal year that ended in Oct. 2015 is calculated as

CardioGenics Holdings's Debt to Equity Ratio for the quarter that ended in Jan. 2016 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CardioGenics Holdings  (OTCPK:CGNH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


CardioGenics Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CardioGenics Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


CardioGenics Holdings (CardioGenics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
6295 Northam Drive, Unit 8, Mississauga, ON, CAN, L4V 1W8
CardioGenics Holdings Inc is a biotechnology company. It is engaged in the development and commercialization of diagnostic test products for the In-Vitro Diagnostics (IVD) testing market. The company's objective is to create, develop and commercialize superior, innovative, cost-effective and patent-protected products for the IVD based on proprietary technologies. Its products include QL Care Analyzer, Immunoassay Tests, and Paramagnetic Beads. The business activity is primarily carried out through the region of Canada.

CardioGenics Holdings (CardioGenics Holdings) Headlines

No Headlines